{
  "hypothesis": "h251",
  "title": "SGLT2 Inhibitor Cross-Category Transfer Analysis",
  "analysis_date": "2026-02-05",
  "precision": 63.9,
  "counts": {
    "total_predictions": 36,
    "clinically_validated": 23,
    "not_validated": 13,
    "unknown": 0
  },
  "validated_indications": {
    "primary_approved": [
      "Type 2 diabetes",
      "Heart failure (HFrEF/HFpEF)",
      "Chronic kidney disease"
    ],
    "validated_repurposing": [
      {
        "indication": "Hypertension",
        "evidence": "3-9 mmHg BP reduction in clinical trials"
      },
      {
        "indication": "Atherosclerosis/ASCVD",
        "evidence": "EMPA-REG: 14% reduction in MACE"
      },
      {
        "indication": "Myocardial infarction",
        "evidence": "Secondary prevention - reduced CV events"
      },
      {
        "indication": "Obesity",
        "evidence": "1.6-2 kg weight loss vs placebo"
      },
      {
        "indication": "Peripheral vascular disease",
        "evidence": "Part of CV risk reduction"
      }
    ]
  },
  "false_positive_patterns": [
    {
      "disease": "Spina bifida",
      "reason": "No biological mechanism"
    },
    {
      "disease": "Tuberous sclerosis complex",
      "reason": "No SGLT2 connection to mTOR pathway"
    },
    {
      "disease": "Hypoparathyroidism",
      "reason": "Wrong calcium pathway"
    },
    {
      "disease": "Hypoglycemia",
      "reason": "SGLT2i cause hypoglycemia - not treat it"
    }
  ],
  "key_finding": "SGLT2 inhibitors show HIGH precision (61%) due to validated pleiotropic effects"
}